Kornimate/medical-research-clean huggingface dataset:
artificial intelligence for highly myopic cataract

Conditions: Cataract; High Myopia; Myopia; Automatic Judgement; Risk Reduction; Diagnoses Disease

Summary: this study aims to establish a multi-center artificial intelligence model for the accurate calculation of intraocular lens and its clinical application in highly myopic cataract, so as to improve the accuracy of the prediction of postoperative diopter in highly myopic cataract patients.

high myopia cataract (hmc) is a complex cataract with high risk of blindness. at present, there are nearly 300 million people with high myopia in the world, which will increase to 500 million by 2020. asia is the high incidence of myopia in the world. at present, there are more than 500 million people with myopia in china alone, of which nearly 100 million are high myopia, and this number is still growing rapidly. correspondingly, the incidence rate of cataract with high myopia has also increased rapidly, which accounts for over 40% of cataract surgery. in the early stage of the project team's analysis of refractive error after high myopia cataract surgery, it was found that the accuracy of intraocular lens calculation formula, which is widely recommended for high myopia cataract at present, is still worrying, because most of these formulas are based on the european and american eye data, while the european and american databases have few ultra high myopia data, which greatly affects the formula's accuracy in addition, the calculation of the existing formula needs to include multiple biometric indicators, and can be obtained based on complex algorithms. artificial intelligence technology is exactly an effective means to solve this kind of problem. therefore, based on the data of asian population with high myopia and high incidence, the establishment of an intelligent model for the accurate calculation of high myopia cataract iol will greatly improve the measurement accuracy sex. therefore, the purpose of this study is to establish a multi-center artificial intelligence model for the accurate calculation of intraocular lens and its clinical application in highly myopic cataract, so as to improve the accuracy of the prediction of postoperative diopter in highly myopic cataract patients.

Eligibility criteria:
inclusion criteria: axial length ≥ 26 mm and patients with high myopia complicated by cataracts who visit our hospital. preoperative anterior segment photography and cataract severity assessment, along with fundus oct examination, have been performed. if surgical treatment is conducted, the postoperative follow-up period should be no less than 1 month. there are no missing clinical data before and after the surgery. exclusion criteria: patients who are unable to cooperate with the required examinations for this study.

Keywords: highly myopic cataract artificial intelligence cataract big data
natural disease progression in participants with choroideremia

Conditions: Choroideremia

Summary: the primary objective of this study is to quantify disease progression measured by best corrected visual acuity (bcva) in the real-world setting among choroideremia (chm) participants. the secondary objectives are to describe demographic and baseline clinical characteristics among chm participants and to match chm participants in the intelligent research in sight (iris®) registry to biogen's investigator sponsored trial (ist) study population using propensity score matching.

this study is a retrospective cohort study of chm eyes and participants which will include all eligible participants and eyes with the first documented diagnosis of chm from july 1st, 2013 to december 31st, 2019 that meet the study criteria. this study will be conducted using data from american academy of ophthalmology's (aao) iris® registry which captures chm participant's demographics, clinical characteristics and clinical outcomes from 2013.

Eligibility criteria:
key inclusion criteria: cohort 1: all chm participants * participants with a documented diagnosis of chm identified by the presence of international classification of diseases (icd)-9/10 or snomed coding: 1. icd-9: 363.55 2. icd-10: h31.2 3. snomed-ct: 75241009 cohort 2: trial-matched chm participants * male participants with a documented diagnosis of chm identified by the presence of icd-9/10 or snomed coding: 1. icd-9: 363.55 2. icd-10: h31.21 3. snomed-ct: 75241009 key exclusion criteria: * n/a note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: x-linked inherited retinal disorder rare disease bilateral disease
a clinical study evaluating the safety and efficacy of bind19 treatment in childhood r/r all and lymphoma subjects

Conditions: Relapsed B-cell Acute Lymphoblastic Leukemia, Childhood; Refractory B-cell Acute Lymphoblastic Leukemia, Childhood; Relapsed/Refractory B-cell Lymphoma, Childhood

Summary: this is a single arm, open-label, uni-center, phase i/ii study to determine the safety and efficacy of an experimental therapy called bind19 cells in childhood patients with b-cell acute lymphoblastic leukemia or lymphoma, who are chemo-refractory, relapsed after allogeneic sct, or are otherwise ineligible for allogeneic stem cell transplant.


Eligibility criteria:
inclusion criteria: * male and female subjects with cd19+ b cell malignancies in patients with no available curative treatment options (such as autologous or allogeneic sct) who have limited prognosis (several months to \< 2 year survival) with currently available therapies will be enrolled. * cd19+ leukemia or lymphoma * not eligible for allogeneic sct because of age, comorbid disease, or lack of available family member or unrelated donor * follicular lymphoma, previously identified as cd19+: * disease responding or stable after most recent therapy (chemotherapy, moab, etc) * ecog result is 0, 1 or 2. * with normal heart, liver and kidney functions. * negative serum dna for ebv and cmv; negative antigen for hbv; negative serum antibody for hcv, hiv and syphilis. * negative in pregnancy test (female subject only). exclusion criteria: * ecog result is 3, 4 or 5. * pregnant or lactating female * uncontrolled active infection * active hepatitis b or hepatitis c infection * concurrent use of systemic steroids. recent or current use of inhaled steroids is not exclusionary * previously treatment with any gene therapy products * hiv infection * enrolled to other clinical study in the last 4 weeks. * subjects with systemic auto-immune disease or immunodeficiency. * subjects with cns diseases. * subjects with secondary tumors. * subjects with tumor infiltration in liver, brain or gi tract.
discrimination of p and t waves with linq and holter

Conditions: Arrhythmias, Cardiac

Summary: currently loop recorders diagnose arrhythmias and send automatic alerts to physicians based on r to r relationships only. we believe arrhythmia diagnostics could be improved if accurate detection of p and t waves as well as qrs complexes were possible. there is no technique available for long term outpatient monitoring of qt intervals for patient at risk of torsade de pointes when receiving qt prolonging drugs. we believe that if an accurate t wave detection algorithm were developed loop recorders could be used to monitor the qt interval, and perhaps even provide alerts for patients at risk. the objective of this study is to see if an algorithm can be developed to accurately define p and t waves using data from an implantable loop recorder.

pilot study of 20 prospective cardiology patients with loop recorders currently implanted for standard clinical indications. eligible subjects will be brought into the office of john wilson, md or marshall winner, md. after informed consent is obtained from hatton research staff the following will be performed: * subjects will have an initial loop recorder download to usb flash drive * 12 lead ekg * annotated qt intervals on a 30 second rhythm strip * 24 hour holter monitor placed by hatton research staff in order to confirm the loop recorder data. * subjects will be instructed on the holter monitors care and use. * subjects will be scheduled to come back to the office after 24 hours to return the holter monitor and have a final loop recorder download completed. * data from the loop recorder, holter monitor, 12 lead ekg, and 30 second rhythm strip will be downloaded and de-identified per hatton research staff. * all de-identified data from the initial loop recorder download, 12 lead ekg, 30 second rhythm strip, final loop recorder download, and holter monitor will be sent to medtronic for algorithm development. independent variables: these variables include age and race dependent variables: these variables include the data from the loop recorder, 12 lead ekg, holter monitor and 30 second rhythm strip. intervention or experimental aspect of the study subjects will have a 12 lead ekg performed with 30 second rhythm strip subjects will complete a period of 24 hours in which they will wear a holter monitor applied by hatton research staff. statistical analysis * descriptive statistics (mean, standard deviation) will be calculated for all continuous variables. continuous variables will be compared using student's - t test or anova as appropriate. * frequency and percentages will be calculated for all categorical variables. * categorical data will be compared using chi square or fisher's exact test as appropriate * data variables will be assessed by hatton research specialist

Eligibility criteria:
inclusion criteria: * subject currently has a medtronic loop recorder implanted * subject has large enough p and t wave amplitudes present per discretion of md. exclusion criteria: * subjects with inadequate sized p and t waves
image guided radiation therapy for prostate cancer

Conditions: Prostate Cancer

Summary: during the 7 to 8 weeks of conformal radiotherapy for prostate carcinoma, the prostate has an intra-pelvic motion which is not detectable by the conventional portal imaging. this prostate motion may lead to a mistargeting, which possibly decreases the local control. on the other hand, the new 3d on board imaging (3d obi) allows to localize the target but is expensive. the cost/effectiveness ratio is not well established, as well as the frequency of using such imaging during the course of radiation.


Eligibility criteria:
inclusion criteria: * prostate adenocarcinoma * intermediate / high risk group * n0 or n - * treatment by conformal radiotherapy (including or not imrt), with or without androgen deprivation exclusion criteria: * pelvic irradiation * metal objects in the pelvis

Keywords: prostate adenocarcinoma treated by radiotherapy
effect of randomization to neuromuscular blockade on physical functional impairment and recovery in ards

Conditions: Acute Respiratory Distress Syndrome; Neuromyopathies

Summary: the proposed work will determine the effect of neuromuscular blockade on physical function and recovery in patients with ards. the investigators will conduct a prospective ancillary study at five petal clinical centers that will evaluate the neuromuscular structure and function of rose (reevaluation of systemic early neuromuscular blockade) patients during and after critical illness, including in-person assessments at 6 months after hospital discharge. the investigators hypothesize that patients randomized to nmb will have an increase in icu-acquired neuromuscular dysfunction during and after critical illness.

the investigators will assess this dysfunction in different ways, appropriate for patients' stage of critical illness and anticipated recovery. during critical illness, the investigators will use nerve conduction studies (ncs) to assess nerve and muscle function, identifying presence of early neuromyopathy (primary outcome, aim 1). additional early assessments will include bedside ultrasound to determine muscle mass and echogenicity, indices of atrophy and loss of muscle architecture. later in acute hospitalization as patients are able to participate in testing, the investigators will use hand grip dynamometry to assess muscle strength (primary outcome, aim 2). additional assessments at this time will be hand held dynamometry to determine proximal muscle strength, dual energy x-ray absorptiometry (dexa) and repeat ultrasound to evaluate muscle mass, and short physical performance battery (sppb) to assess activity. after hospital discharge-at 6 months after ards-the investigators will assess activity in-person using the sppb (primary outcome, aim 3). additional post-hospital assessments include detailed evaluation of healthcare utilization, six minute walk testing (6mwt) to determine endurance, and repetition of previous assessments of muscle structure, function and strength to provide novel, detailed information of recovery process. each aim tests a distinct hypothesis of the effect of randomization to nmb on icu-acquired neuromuscular dysfunction, investigating different time points and aspects of physical function, so aims are not interdependent. for example, it is plausible that the direct toxicity of nmb on muscle will lead to early evidence of neuromyopathy, manifest as reduced muscle depolarization amplitudes with nerve stimulation. but if nmb attenuates lung injury, strength may be improved by hospital discharge, despite early injury to muscle.

Eligibility criteria:
inclusion criteria: * patients must be enrolled in the petal network's rose study * patients must have at least one complete leg exclusion criteria: * complete spinal cord injury with deficits at level t1 or above * severe peripheral neuromuscular disease (specifically motor neuron disease (als) or acute guillain-barre syndrome) * inability to obtain informed consent
clinical trial to assess safety of si-6603 in patients with lumbar disc herniation

Conditions: Lumbar Vertebra Hernia

Summary: the purpose of this study is to evaluate the safety of si-6603 in lumbar disc herniation patients.


Eligibility criteria:
inclusion criteria: * patients with lumbar disc herniation (l4-l5 or l5-s1) as assessed by mri and clinical symptoms corresponding to position of the impaired nerve root. * patients assessed as positive in the slr test. * patients with sciatica in either lower leg. * patients with no improvement from pharmacotherapy or concomitant treatment with drug and nerve block. exclusion criteria: * patients who have 2 or more lumbar disc herniations as assessed by mri. * patients with "extrusion-type" or "sequestration-type" herniation in whom a rupture into the posterior longitudinal ligament is identified by mri. * patients who have received nerve block within 3 weeks before screening. * patients who have undergone lumbar operation, chemonucleolysis, or percutaneous nucleotomy.

Keywords: chemonucleolysis lumbar vertebrae hernia
quality of life in middle-aged and older patients with congenital ichthyosis

Conditions: Congenital Ichthyosis

Summary: the goal of this observational study is to learn about the quality of life in patients with congenital ichthyosis. the main question it aims to answer are: • what is the impact of ichthyosis on the biological-psychological-social quality of life in adult and elderly patients with inherited ichthyosis ? participants will take part in individual interviews in which the investigators will explore if and how ichthyosis impacts their quality of life. examples of such questions are whether participants experience pain, experience struggles in their personal or professional lives, with sports activities or if participants experience a financial burden.

there is limited knowledge on factors affecting the quality of life in patients with ichthyosis, especially in middle-aged and elderly patients. with this study the investigators aim to study the impact of inherited ichthyosis on the biological-psychological-social quality of life in adult and elderly patients with ichthyosis. secondary research questions include: 1. what is the impact of ichthyosis on the biological quality of life; by analysing physical complaints, adverse events and drug management in patients with long-term medication use of both topical and systemic treatments, and discussing the sexual health and reproductive challenges? 2. what is the impact of ichthyosis on the psychological quality of life; by examining patients' self-esteem and any clinical symptoms of body dysmorphic disorder, and mental and emotional complaints such as concerns about their future care? 3. what is the impact of ichthyosis on the social quality of life; by analysing interpersonal relationships, social support dynamics, societal costs and awareness, and career opportunities? furthermore the investigators aim to discover knowledge gaps in current patient management and possible areas of improvement in patient care towards health professionals.

Eligibility criteria:
inclusion criteria: * 30 years of age and older * clinical or genetic confirmed variant of congenital ichthyosis exclusion criteria: * \<30 years of age * ichthyosis vulgaris * another primary chronic skin condition besides ichthyosis * patients who are not able to read/speak dutch
comparison of the effects of qlb 2 and qlb 3 on post-operative analgesia in cesarean section surgery

Conditions: Analgesia; Acute Pain; Chronic Pain

Summary: this study evaluates the post-operative analgesic effects of quadratus lomborum block 2 and 3 (qlb 2, 3) in patients having cesarean section with spinal anesthesia. spinal anesthesia will be performed to all patients for the surgery.

in this study, patients are divided into two groups. after the spinal anesthesia is performed and cesarean section surgery is over; qlb 2 block will be performed to patients in group a ; while qlb 3 block will be performed to patients in group b. in addition, patient controlled analgesia (pca) will be used in the first 24 hours postoperatively. group a - patients in group a will have qlb 2 block after the surgery. in addition, patient controlled analgesia (pca) will be used in the first 24 hours postoperatively. group b - patients in group b will have qlb 3 block after the surgery. in addition, patient controlled analgesia (pca) will be used in the first 24 hours postoperatively.

Eligibility criteria:
inclusion criteria: * being pregnant for at least 37 weeks * planning an elective cesarean operation * being between the ages of 18-45 exclusion criteria: * asa 3-4 patients with comorbitidies (serious renal, cardiac, hepatic disease) * being operated with general anesthesia * obesity (\> 100 kg, bmi\> 35 kg / m2) * contraindication of regional anesthesia (quagulopathy, abnormal inr, thrombocytopenia, infection at the injection site) * hypersensitivity to local anesthetics or a history of allergy * patients with a history of opioid use longer than four weeks * patients with psychiatric disorders * patients with anatomic deformity * patients who do not want to participate

Keywords: regional anesthesia acute and chronical pain quadratus lumborum blocks cesarean section spinal anesthesia
effects of binaural beats on inhaled anesthetic requirements during general anesthesia in pediatric patients

Conditions: General Anesthesia; Children

Summary: the hypothesis of this study is that continuously delivering binaural beats with a phase difference corresponding to the slow-delta frequency band during anesthesia in pediatric patients can clinically and significantly reduce the required dose of the commonly used inhalational anesthetic, sevoflurane. to test this hypothesis, the study will compare the average end-tidal concentration of sevoflurane between a group exposed to continuous binaural beats (approximately 1 hz phase difference) during surgery and a control group not exposed to such auditory stimulation.


Eligibility criteria:
inclusion criteria: 1. pediatric patients under 3 years of age undergoing superficial surgery lasting more than 1 hour under general anesthesia (e.g., nevus excision, polydactyly/syndactyly surgery, dermoid cyst excision, thyroglossal duct cyst excision, preauricular fistula excision, inguinal hernia repair, orchiopexy, other mass excisions, strabismus surgery, etc.). 2. american society of anesthesiologists (asa) physical status classification i or ii. exclusion criteria: * neonates or premature infants * children with hearing impairment or currently using hearing aids * children with neurological disorders * children with respiratory diseases * children undergoing neurosurgery or cardiac surgery * other patients deemed inappropriate for inclusion in the clinical trial at the discretion of the investigator or study staff
high fresh gas flow after intubation

Conditions: Atelectasis

Summary: atelectasis is common during and after general anesthesia. atelectasis develops early if preoxygenation with 100% oxygen is used and continuously used during induction until endotracheal intubation. the investigators hypothesize that a rapid anti-preoxygenation maneuver immediately after confirming a successful intubation, reduces the area of atelectasis as investigated by computed tomography compared to a standard procedure.


Eligibility criteria:
inclusion criteria: * healthy patients, american society of anesthesiology (asa) i-ii * patients scheduled for orthopaedic day case surgery in general anaesthesia exclusion criteria: * asa class iii or higher * body mass index (bmi) 30 or higher * arterial oxygen saturation (spo2) \<94% breathing air * chronic obstructive pulmonary disease (copd) * ischemic heart disease * haemoglobin \<100g/l * known or anticipated difficult airway and/or intubation * active smokers and ex-smokers with a history of more than 6 pack years * need for interscalene or supraclavicular regional anaesthesia with risk of phrenic nerve paralysis

Keywords: atelectasis fresh gas flow prevention oxygenation anaesthesia
cardiovascular function and ribavirin pharmacokinetics and pharmacodynamics in patients with lassa fever

Conditions: Lassa Fever

Summary: lassa fever carries a treated mortality in hospitalized patients of up to 50%. lassa fever is often described as being characterized by vascular leak and shock in the terminal phase, but, whilst animal data supports this, there are limited data in humans. therefore, an aim of this study therefore is to characterize cardiovascular function in patients with lassa fever, with the ultimate goal of informing future trials of supportive or therapeutic strategies. ribavirin is the current standard of care. however, the efficacy of ribavirin has not been established in a randomised controlled trial (rct). there is very limited pharmacokinetic (pk) data on ribavirin in patients with lassa fever and the optimal dose of ribavirin for an rct is unknown. furthermore, there are various hypothesized mechanisms of action of ribavirin, none of which have been investigated in humans with lassa fever. further aims of this study therefore are to characterize the pk of ribavirin in lassa fever, and identify any associations between ribavirin pk parameters, viral load and markers of immune/inflammatory status.


Eligibility criteria:
inclusion criteria: * positive antigen or pcr test for lassa fever * aged 10 years or above exclusion criteria: * patients for end of life care only